2,111 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Altfest L J & Co. Inc.

Key Points

• Altfest L J & Co. Inc. has acquired a new position in Ascendis Pharma A/S, purchasing 2,111 shares valued at approximately $329,000.
• Several institutional investors have recently adjusted their stakes in Ascendis Pharma, with notable increases from PNC Financial Services Group and GF Fund Management CO. LTD.
• Brokerage firms have set new price targets for Ascendis Pharma, with Evercore ISI and Citigroup raising their targets to $280.00 and $243.00 respectively, indicating a generally positive outlook.

Altfest L J & Co. Inc. purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,111 shares of the biotechnology company's stock, valued at approximately $329,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Virtus ETF Advisers LLC lifted its position in Ascendis Pharma A/S by 3.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after buying an additional 100 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Ascendis Pharma A/S by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company's stock worth $1,337,000 after buying an additional 195 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth about $28,000. GF Fund Management CO. LTD. lifted its position in Ascendis Pharma A/S by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock worth $241,000 after buying an additional 278 shares in the last quarter. Finally, Mariner LLC lifted its position in Ascendis Pharma A/S by 31.0% during the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock worth $297,000 after buying an additional 511 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $190.35 on Friday. The stock has a market cap of $11.64 billion, a PE ratio of -30.31 and a beta of 0.41. The stock has a 50-day moving average of $173.47 and a 200-day moving average of $158.42. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $190.35.

Analysts Set New Price Targets

Several brokerages recently issued reports on ASND. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Morgan Stanley began coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. Citigroup boosted their price objective on Ascendis Pharma A/S from $213.00 to $243.00 and gave the stock a "buy" rating in a report on Friday, July 11th. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $245.00 to $254.00 and gave the stock an "overweight" rating in a report on Tuesday, July 29th. Finally, Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average price target of $223.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.